# **Refine Search**


### Search Results -


Terms	Documents
tocopher\$ adj10 suppository	5

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:









## **Search History**

DATE: Thursday, March 02, 2006 Prints

Printable Copy Create Case

Set Name	Query	Hit Count	Set Name
side by side			result set
DB = USP'	T,EPAB,JPAB,DWPI,TDBD; PLUR=1	YES; OP=OR	
<u>L3</u>	tocopher\$ adj10 suppository	5	<u>L3</u>
<u>L2</u>	tocopher\$ adj5 suppository	2	<u>L2</u>
<u>L1</u>	tocopher\$ same suppository	100	<u>L1</u>

END OF SEARCH HISTORY

First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Generate Collection Print

L3: Entry 2 of 5

File: USPT

Mar 27, 1984

DOCUMENT-IDENTIFIER: US 4439432 A

TITLE: Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols

#### Brief Summary Text (1):

The present invention relates to the composition of a biologically compatible high concentration solution of progesterone in tocopherol, with or without modifying substances, which can be used transdermally, orally, and in suppository and pessary form, for the correction of progesterone deficiency states and other diseases.

**Interrupt** 

# Refine Search

### Search Results -

Terms	Documents
soy\$ adj5 (phosphatidylcholine adj5 linol\$)	2

US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database Database: **EPO Abstracts Database** JPO Abstracts Database **Derwent World Patents Index IBM Technical Disclosure Bulletins** L8 Search: Refine Search Recall Text < Clear

## **Search History**

DATE: Thursday, March 02, 2006 Printable Copy Create Case

Set Name side by side	- ·	Hit Count	Set Name result set
DB=US	SPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR		
<u>L8</u>	soy\$ adj5 (phosphatidylcholine adj5 linol\$)	. 2	<u>L8</u>
<u>L7</u>	(liposome) same (phosphatidylcholine adj5 linol\$)	11	<u>L7</u>
<u>L6</u>	(tocopher\$) same liposome same (linol\$)	21	<u>L6</u>
<u>L5</u>	(tocopher\$) same liposome same (phosphatidylcholine) same (linol\$)	8	<u>L5</u>
<u>L4</u>	(tocopher\$) same liposome same (soy\$ adj3 phosphatidylcholine)	11	<u>L4</u>
<u>L3</u>	(vitamin adj1 E) same liposome same (soy\$ adj3 phosphatidylcholine)	4	<u>L3</u>
<u>L2</u>	(vitamin adj1 E) same liposome same (soy\$ adj3 lecithin)	1	<u>L2</u>
L1	(vitamin adj1 E) same liposome same (soy adj3 lecithin)	0	L1

**END OF SEARCH HISTORY** 

First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Generate Collection Print'

L4: Entry 6 of 11

File: USPT

Jun 24, 1997

DOCUMENT-IDENTIFIER: US 5641758 A

TITLE: Cytarabine derivatives, the preparation and use thereof

### Detailed Description Text (16):

To prepare the <a href="liposome">liposome</a> dispersion, the following were dissolved per ml of 1/1 chloroform/methanol (v/v): 100 mg of <a href="south south so

First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Cénérate Collection Print

L7: Entry 6 of 11

File: USPT

Jun 19, 1990

DOCUMENT-IDENTIFIER: US 4935244 A

TITLE: Nedocromil sodium compositions and methods for their preparation

#### Brief Summary Text (11):

A wide variety of lipid materials may be used to form the liposomes including natural lecithins, e.g. those derived from egg and soya bean, and synthetic lecithins. Lipids which are non-immunogenic and bio-degradable are preferred. The properties of the lipid, for example its phase transition temperature, can have a marked effect on the retention and uptake of the liposomes in the target organ and for this reason the well defined synthetic lecithins are preferred to the natural lecithins. Examples of synthetic lecithins which may be used, together with their respective phase transition temperatures, are di-(tetradecanoyl)phosphatidylcholine (DTPC) (23.degree. C.), di-(hexadecanoyl)phosphatidylcholine (DHPC) (41.degree. C.) and di-(octadecanoyl)phosphatidylcholine (DOPC) (55.degree. C.). We prefer to use di-(hexadecanoyl) phosphatidylcholine as the sole or major lecithin, optionally together with a minor proportion of the di-(octadecanoyl) or the di-(tetradecanoyl) compound. Other synthetic lecithins which may be used are unsaturated synthetic lecithins, for example di-(oleyl)phosphatidylcholine and di-(linoleyl) phosphatidylcholine. We prefer the synthetic lecithin, or the mixture of lipids, to have a phase transition temperature in the range 35.degree.-45.degree. C. In addition to the main liposome-forming lipid or lipids, which are usually phospholipids, other lipids (e.g. in a proportion of 5-40% w/w of the total lipids) may be included, for example cholesterol or cholesterol stearate, to modify the structure of the <a href="liposome">liposome</a> membrane, rendering it more fluid or more rigid depending on the nature of the main liposome-forming lipid or lipids. An optional third component is a material which provides a negative charge, for example phosphatidic acid, dicetyl phosphate or beef brain ganglioside, or one which provides a positive charge for example stearylamine acetate or cetylpyridinium chloride. The charged component may be included in a proportion of 1-20% w/w of the total lipids.

First Hit

**Previous Doc** 

Next Doc

Go to Doc#

**End of Result Set** 

Cenerate Collection
Print

L2: Entry 2 of 2

File: DWPI

DERWENT-ACC-NO: 1966-01557F

DERWENT-WEEK: 200397

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Suppository compn

PATENT-ASSIGNEE: DEBARGE AEJJ (DEBA)

Search ALL Clear

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

000

MAIN-IPC

FR 808 M

ABSTRACTED-PUB-NO: FR 808M

BASIC-ABSTRACT:

New suppository composition consists of 0.26 g ethyl guaiacolglycolate, 0.10 g. synthetic camphor, 0.05 g. eucalyptol, 0.01 g. amylein hydrochloride, 0.40 g. acetylsalicylic acid, 0.15 g. basic quinine sulphate, 0.10 g. glycocoll, 0.00035 g. DL alpha-tocopherol, cocoa butter to 3.5 g. The suppositories are used to treat broncho-pulmonary infections and the tocopherol is included in the excipient as well as glycocoll to prevent hydrolysis of the acetylsalicylic acid.

ABSTRACTED-PUB-NO: FR 808M EQUIVALENT-ABSTRACTS:

DERWENT-CLASS: B00

CPI-CODES: B03-H; B04-A02; B04-B01; B06-A02; B10-B02; B10-C03; B10-E04; B10-F02;

B12-K06; B12-M08;